3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
185
Neoplasms
178
Carcinoma, Non-Small-Cell Lung
162
Prostatic Neoplasms
114
Colorectal Neoplasms
111
Lung Neoplasms
94
Ovarian Neoplasms
85
Neoplasm Metastasis
80
Multiple Myeloma
75
Pancreatic Neoplasms
73
Leukemia, Myeloid, Acute
68
Endometrial Neoplasms
53
Stomach Neoplasms
49
Squamous Cell Carcinoma of Head and Neck
48
Melanoma
48
Lymphoma
46
Glioblastoma
45
Recurrence
44
Carcinoma, Renal Cell
44
Urinary Bladder Neoplasms
42
Carcinoma, Hepatocellular
41
Brain Neoplasms
41
Precursor Cell Lymphoblastic Leukemia-Lymphoma
40
Sarcoma
38
Lymphoma, Non-Hodgkin
36
Leukemia, Lymphocytic, Chronic, B-Cell
36
Glioma
36
Hematologic Neoplasms
35
Small Cell Lung Carcinoma
34
Esophageal Neoplasms
33
Interventions
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Fibrosis
×
30 days
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled